The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Abeona Therapeutics Inc COM 00289Y107 40,234 2,359,767 SH   SOLE   2,359,767 0 0
Advaxis Inc. W EXP 07/15/201 007624117 191 112,500 SH   SOLE   112,500 0 0
Alcobra Ltd SHS M2239P109 812 804,049 SH   SOLE   804,049 0 0
Aldeyra Therapeutics Inc COM 01438T106 893 124,096 SH   SOLE   124,096 0 0
Ampio Pharmaceuticals Inc. COM 03209T109 1,609 2,595,484 SH   SOLE   2,595,484 0 0
Anavex Life Sciences Corp COM NEW 032797300 2,998 724,205 SH   SOLE   724,205 0 0
Biohaven Pharmactl Hldg Co L COM G11196105 30,150 807,224 SH   SOLE   807,224 0 0
Caladrius Biosciences Inc COM NEW 128058203 422 117,957 SH   SOLE   117,957 0 0
Corbus Pharmaceuticals HLDGS COM 21833P103 26,733 3,738,925 SH   SOLE   3,738,925 0 0
Evoke Pharma Inc COM 30049G104 752 225,000 SH   SOLE   225,000 0 0
Keryx Biopharmaceuticals Inc. COM 492515101 1,420 200,000 SH   SOLE   200,000 0 0
Krystal Biotech Inc COM 501147102 2,991 300,000 SH   SOLE   300,000 0 0
Lipocine Inc New COM 53630X104 99 25,000 SH   SOLE   25,000 0 0
Summit Therapeutics PLC SPONS ADS 86627R102 1,152 91,800 SH   SOLE   91,800 0 0
Vascular Biogenics LTD COM M96883109 5,250 860,605 SH   SOLE   860,605 0 0
Volition RX LTD COM 928661107 1,242 461,538 SH   SOLE   461,538 0 0